Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Prothena Corporation plc today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680). Based ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

Diabetes is a leading global health and economic challenge, affecting over 800 million people worldwide, with over 80% ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

2-Year U.S. Treasury Note Continuous Contract $103.293-0.066-0.06% 5-Year U.S. Treasury Note Continuous Contract $107.469-0.258-0.24% 10-Year U.S. Treasury Note Continuous Contract $109.766-0.438 ...